• Home
  • NEW DAY MEDICINE
  • 9 (59) 2023
  • 31 -9 (59) 2023 — Xalilova D.Z., Alieva A.V. — CONSEQUENCES OF CORONAVIRUS INFECTION IN PATIENTS WITH DIABETES MELLITUS DEPENDING ON GLOW-LOWING THERAPY

31 -9 (59) 2023 — Xalilova D.Z., Alieva A.V. — CONSEQUENCES OF CORONAVIRUS INFECTION IN PATIENTS WITH DIABETES MELLITUS DEPENDING ON GLOW-LOWING THERAPY

CONSEQUENCES OF CORONAVIRUS INFECTION IN PATIENTS WITH DIABETES MELLITUS DEPENDING ON GLOW-LOWING THERAPY

Xalilova D.Z., Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y. Kh. Turakulov, specialized hospital

Alieva A.V. Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y. Kh. Turakulov, specialized hospital

Resume

Analysis of the effect of glucose-lowering therapy on the consequences of coronavirus infection seems to be an urgent task.

Objective: to study the effect of therapy received by patients with diabetes on the consequences of COVID-19.

Materials and methods: we analyzed a cohort of patients with type 1 (213 patients) and type 2 (763 patients) diabetes who had COVID-19 in 2020. Of these, 234 patients were selected (120 men (51.28%) and 114 women (48.72%)), in whom hypoglycemic therapy did not change for at least 6 months preceding the coronavirus infection.

Results: The consequences of coronavirus infection in patients with type 2 diabetes are not limited to thrombotic complications. There is a progression of chronic complications of diabetes, the emergence of new cases of arterial hypertension, the development of depression, and purulent complications. The lower risk of developing post-Covid complications when taking biguanides and sodium-glucose co-transporter type 2 inhibitors (iSGLT2) suggests the advantage of prescribing drugs from these groups when new cases of coronavirus infections occur.

Key words: diabetes mellitus, COVID-19, hypoglycemic therapy.

First page

171

Last page

178

For citation: Xalilova D.Z., Alieva A.V. – CONSEQUENCES OF CORONAVIRUS INFECTION IN PATIENTS WITH DIABETES MELLITUS DEPENDING ON GLOW-LOWING THERAPY //New Day in Medicine 2023 9 (59): 171-178 https://newdaymedicine.com/index.php/2023/09/14/l-369/

LIST OF REFERENCES:

  1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020; S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017 pmid:32173574
  2. Ma R.C.W. Holt R.I.G. COVID-19 and diabetes. Diabet Med. 2020; https://doi.org/10.1111/dme.14300
  3. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-1515.
  4. Bramante C.T., Ingraham N.E., Murray T.A., Marmor S., Hovertsen S., Gronski J., et al. Metformin and risk of mortality in patients hospitalized with Covid-19: a retrospective cohort analysis. //Lancet Healthy Longev. 2021;2:e34-41. Published on line December 2020;3. https://doi.org/10.1016/S2666-7568(20)30033-7.
  5. Crouse A.B., Grimes T., Li P., Might M., Ovalle F., Shalev A. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. //Front Endocrinol (Lausanne). Jan 13 2021;11/600439:1-8. doi: 10.3389/fendo.2020.600439. PMID: 33519709; PMCID: PMC7838490.
  6. Ghany R, Palacio A, Dawkins E, Chen G, McCarter D, Forbes E, Chung B, Tamariz L. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. //Diabetes Metab Syndr. Mar-Apr; 2021;15(2):513-518. doi: 10.1016/j.dsx.2021.02.022. Epub 2021 Feb 18. PMID: 33662839; PMCID: PMC7891082.
  7. Li J., Wei Q., Li W.X., McCowen K.C., Xiong W., Liu J., et al. Metformin use in diabetes prior to hospitalization: effects on mortality in COVID-19. Endocrine practice. 2020;26(10 October):1166-1172.
  8. Lukito AA, Pranata R, Henrina J, Lim MA, Lawrensia S, Suastika K. The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. Nov-Dec2020;14(6):2177-2183. doi: 10.1016/j.dsx.2020.11.006. Epub 2020 Nov 11. PMID: 33395778; PMCID: PMC7657016.
  9. Luo P., Qiu L., Liu Y., Liu X.L., Zheng J.L., Xue H.Y., et al. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. //Am J Trop Med Hyg. Jul 2020;103(1):69-72. doi: 10.4269/ajtmh.20-0375. Epub 2020 May 21. PMID: 32446312; PMCID: PMC7356425.
  10. Mendy A, Gopal R, Alcorn JF, Forno E. Reduced mortality fromlower respiratory tract disease in adult diabetic patientstreated with metformin. Respirology. 2019;24(7):646-651. doi: 10.1111/resp.13486. Epub 2019 Feb 13. PMID: 30761687; PMCID: PMC6579707.
  11. Scheen A.J. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab. 2020;46(6):423-426. doi: 10.1016/j.diabet.2020.07.006. Epub 2020 Aug 1. PMID: 32750451; PMCID: PMC7395819.
  12. Xian H., Liu Y., Rundberg Nilsson A., Gatchalian R., Crother T.R., Tourtellotte W.G., Zhang Y., et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. Jul 13 2021;54(7):1463-1477.e11. doi: 10.1016/j.immuni.2021.05.004. Epub 2021 Jun 10. PMID: 34115964; PMCID: PMC8189765.
  13. Xin G, Wei Z, Ji C, Zheng H, Gu J, Ma L, Huang W, Morris-Natschke SL, Yeh JL, Zhang R, Qin C, Wen L, Xing Z, Cao Y, Xia Q, Lu Y, Li K, Niu H, Lee KH, Huang W. Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. Sci Rep. Nov  2016;36222:1-12. doi: 10.1038/srep36222. PMID: 27805009; PMCID: PMC5090250.
  14. Schuiveling M., Vazirpanah N., Radstake T.R.D.J., Zimmermann M., Broen J.C.A. Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease? Curr Drug Targets. 2018;19(8):945-959. doi: 10.2174/1389450118666170613081730. PMID: 28606032.
  15. Tsoyi K., Jang H.J., Nizamutdinova I.T., Kim Y.M., Lee Y.S., Kim H.J., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. British journal of pharmacology. 2011;162(7):1498-508.
  16. Victor V.M., Rovira-Llopis S., Bañuls C., Diaz-Morales N., Lopez-Domenech S., Escribano-López I., et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. //Atherosclerosis. 2015;242(1):167-173. doi: 10.1016/j.atherosclerosis.2015.07.017. Epub 2015 Jul 10. PMID: 26188541.
  17. Hughes W.T., Smith-McCain B.L. Effects of sulfonylurea compounds on Pneumocystis carinii. //J Infect Dis. May 1986;153(5):944-947. doi: 10.1093/infdis/153.5.944. PMID: 3486236.
  18. Wargny M., Potier L., Gourdy P., Pichelin M., Amadou C., Benhamou P.Y., et al; CORONADO investigators. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia. Apr 2021;64(4):778-794. doi: 10.1007/s00125-020-05351-w. Epub 2021 Feb 17. PMID: 33599800; PMCID: PMC7890396.
  19. Fadini G.P., Morieri M.L., Longato E., Bonora B.M., Pinelli S., Selmin E., et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. Oct 2020;22(10):1946-1950. doi: 10.1111/dom.14097. Epub 2020 Jul 1. PMID: 32463179; PMCID: PMC7283835.

file

download